158 results on '"Zeidler, Claudia"'
Search Results
2. Clinical aspects and management of chronic itch
- Author
-
Zeidler, Claudia, Raap, Ulrike, Witte, Felix, and Ständer, Sonja
- Published
- 2023
- Full Text
- View/download PDF
3. Transcriptomic, Epigenomic, and Neuroanatomic Signatures Differ in Chronic Prurigo, Atopic Dermatitis, and Brachioradial Pruritus
- Author
-
Agelopoulos, Konstantin, Renkhold, Lina, Wiegmann, Henning, Dugas, Martin, Süer, Aysenur, Zeidler, Claudia, Schmelz, Martin, Pereira, Manuel P., and Ständer, Sonja
- Published
- 2023
- Full Text
- View/download PDF
4. Pruritus in Pregnancy
- Author
-
Stefaniak, Aleksandra A., Pereira, Manuel P., Zeidler, Claudia, and Ständer, Sonja
- Published
- 2022
- Full Text
- View/download PDF
5. Interleukin Profiling in Atopic Dermatitis and Chronic Nodular Prurigo.
- Author
-
Wiegmann, Henning, Renkhold, Lina, Zeidler, Claudia, Agelopoulos, Konstantin, and Ständer, Sonja
- Abstract
The clinical manifestations of atopic dermatitis (AD) and chronic nodular prurigo (CNPG) include pruritus and eczema/lesions, posing significant challenges for patients. Th2 cells and ILC2, marked by cytokine production—particularly IL-4/13—are crucial therapeutic targets. Despite displaying a dose-dependent lack of pruritus induction post-injection, IL-13 acts through the IL-13Rα1 and IL-13Rα2 receptor system. Our study focused on investigating ex vivo skin biopsies in AD (n = 17), CNPG (n = 14) and healthy controls (HC; n = 10), examining the gene expression landscape of interleukins linked with pruritus (IL-13, IL-4, IL-31) and their corresponding receptors. Compared to HC, results revealed a significant upregulation of IL-4, IL-13, and IL-13RA1 in AD, whereas CNPG did not show increased IL13 expression. Notably, the decoy receptor IL-13RA2 displayed intriguing patterns, with AD showing a marked increase compared to both HC and CNPG. Positive correlations between receptor expression and itch intensity and hyperkinesis sensation underscore clinical relevance, potentially serving as biomarkers. The findings suggest a pivotal role of IL-4 and IL-13, along with IL-13RA1, in pruritus pathogenesis in both entities, while IL-13 upregulation in AD is countered by IL-13RA2. The comparable expression of IL-13RA2 to HC in CNPG suggests the absence of this regulatory mechanism, potentially worsening the disease and leading to prolonged scratching behavior. These insights illuminate the intricate interplay of interleukins and receptors in different pruritus phenotypes, laying the groundwork for understanding underlying mechanisms and offering avenues for therapeutic intervention. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Chronic Prurigo.
- Author
-
Thünemann, Julia, Müller, Svenja, Steinbrink, Kerstin, Ständer, Sonja, and Zeidler, Claudia
- Abstract
Summary: Chronic prurigo (CPG) is a neuroinflammatory dermatosis characterized by prolonged pruritus lasting more than 6 weeks, pruriginous skin lesions, and repeated scratching. Patients with CPG suffer significantly from psychological distress and a marked impairment in their quality of life. The most common subtype of CPG is chronic nodular prurigo (CNPG, also called prurigo nodularis). In addition to the clinical features of CPG and the burden of disease, this CME article provides an overview of the significant advances in understanding the pathophysiology, including the associated therapeutic options for CPG. Dupilumab is the first approved therapy for moderate and severe CNPG to date from the European Medicines Agency (EMA) and the US Food & Drug Administration (FDA). It also highlights other agents currently being studied in Phase II and Phase III clinical, randomized, placebo‐controlled trials. These include biologics such as nemolizumab (anti‐IL‐31‐RA‐mAb), vixarelimab/KPL‐716 (anti‐Oncostatin‐M receptor β‐mAb), and barzolvolimab/CDX‐0159 (anti‐KIT‐mAb), as well as Janus kinase inhibitors such as povorcitinib/INCB054707 and abrocitinib, and opioid modulators such as nalbuphine. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Severity stages of chronic nodular prurigo: analysis of associated itch intensity and quality of life impairment
- Author
-
Zeidler, Claudia, Pereira, Manuel P., Storck, Michael, Suer, Aysenur, and Ständer, Sonja
- Published
- 2022
- Full Text
- View/download PDF
8. Validation of a scoring algorithm for the clinician‐reported outcome tool ‘prurigo activity and severity (PAS)’ based on clinical studies of dupilumab in adults with prurigo Nodularis.
- Author
-
Zeidler, Claudia, Stander, Sonja, Rhoten, Stephanie, Wratten, Samantha, Zhang, Dian, Msihid, Jerome, Brookes, Ella, Thomas, Ryan, and Bahloul, Donia
- Abstract
Background Objectives Methods Results Conclusions Prurigo nodularis (PN) also known as chronic prurigo, is a chronic inflammatory skin disease characterized by intensely itchy nodules/lesions which occur due to intensive scratching. PN management is, in part, based on clinician evaluations of PN lesions, which can be supported by clinician‐reported outcomes (ClinRO) such as the Prurigo Activity and Severity (PAS) instrument. A 5‐item version of PAS was included in recent phase‐3 dupilumab PN trials (PRIME [NCT04183335]/PRIME2 [NCT04202679]). The PAS score was derived using the unweighted sum of 3‐items of the 5‐item PAS (range, 0–11; higher score indicates worse activity and severity): Item 2 (number of lesions), Item 5a (percentage of lesions with excoriations/crusts) and Item 5b (percentage of healed lesions) for use in clinical practice and for communication of treatment benefit to physicians.To evaluate the measurement properties of PAS score and derive within‐patient (responder definition) and between‐group improvement thresholds for interpreting changes in PAS score in patients with PN.The data source was the pooled treatment group, intention‐to‐treat (ITT) data from the phase‐3 PRIME (NCT04183335) and PRIME2 (NCT04202679) studies evaluating the efficacy of dupilumab in adult patients with PN with ≥20 nodules and severe itch uncontrolled with topical therapies. PAS score reliability, validity and sensitivity to change were evaluated, and anchor‐ and distribution‐based methods were applied to derive meaningful change thresholds.The pooled ITT population included 311 patients (mean age 49.5 years, 65.3% female). Adequate to good psychometric properties were demonstrated for PAS score. The within‐patient meaningful improvement threshold was estimated as 3.0 points (absolute change) and 37% (per cent change). A 1.7‐point (absolute change) and 20% (per cent change) improvement were estimated to reflect a between‐group meaningful change in PAS score.PAS score is a simple, clinically relevant indicator of PN lesion activity and severity supported by suitable psychometric performance. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Peripheral Sensitization and Loss of Descending Inhibition Is a Hallmark of Chronic Pruritus
- Author
-
Pogatzki-Zahn, Esther M., Pereira, Manuel P., Cremer, Alexander, Zeidler, Claudia, Dreyer, Tim, Riepe, Claudia, Wempe, Carola, Lotts, Tobias, Segelcke, Daniel, Ringkamp, Matthias, Kremer, Andreas E., Agelopoulos, Konstantin, and Ständer, Sonja
- Published
- 2020
- Full Text
- View/download PDF
10. The Neuromodulatory Effect of Antipruritic Treatment of Chronic Prurigo
- Author
-
Zeidler, Claudia, Pereira, Manuel, and Ständer, Sonja
- Published
- 2019
- Full Text
- View/download PDF
11. Development and Validation of a Patient-Reported Outcome Measure to Assess Disease Control in Chronic Prurigo.
- Author
-
Metz, Martin, Zeidler, Claudia, Hawro, Tomasz, Pereira, Manuel, Maurer, Marcus, Bonnekoh, Hanna, Krause, Karoline, Pritchard, Thomas, Kwatra, Shawn G., Ständer, Sonja, and Weller, Karsten
- Published
- 2024
- Full Text
- View/download PDF
12. Validation of the labeled magnitude scale for the assessment of itch intensity in patients with chronic pruritus
- Author
-
Zeidler, Claudia, Röchter, Marvin, Ständer, Sonja, and Pereira, Manuel P.
- Published
- 2021
- Full Text
- View/download PDF
13. IFSI-guideline on chronic prurigo including prurigo nodularis
- Author
-
Ständer, Sonja, Pereira, Manuel P., Berger, Timothy, Zeidler, Claudia, Augustin, Matthias, Bobko, Svetlana, Brenaut, Emilie, Chen, Suephy C., Chisolm, Sarah, Dalgard, Florence J., Elberling, Jesper, Elmariah, Sarina B., Evers, Andrea W.M., Garcovich, Simone, Gonçalo, Margarida, Halvorsen, Jon A., Kim, Brian S., Kupfer, Jörg, Kwatra, Shawn G., Lambert, Julien, Legat, Franz J., Lerner, Ethan A., Leslie, Tabi A., Lönndahl, Louise, Lvov, Andrey, Metz, Martin, Misery, Laurent, Papadavid, Evangelia, Potekaev, Nikolay N., Reich, Adam, Savk, Ekin, Schneider, Gudrun, Schut, Christina, Serra-Baldrich, Esther, Ständer, Hartmut F., Streit, Markus, Szepietowski, Jacek C., Tharp, Michael D., Wallengren, Joanna, Nast, Alexander, Weisshaar, Elke, and Yosipovitch, Gil
- Published
- 2020
- Full Text
- View/download PDF
14. Scratching increases epidermal neuronal branching and alters psychophysical testing responses in atopic dermatitis and brachioradial pruritus.
- Author
-
Renkhold, Lina, Wiegmann, Henning, Pfleiderer, Bettina, Süer, Aysenur, Zeidler, Claudia, Pereira, Manuel P., Schmelz, Martin, Ständer, Sonja, and Agelopoulos, Konstantin
- Subjects
ITCHING ,ATOPIC dermatitis ,NERVE fibers ,NEUROANATOMY ,SENSES - Abstract
Background: Chronic scratching imposes a major stress on the skin and can lead to itch intensity worsening, and consequently, patients may enter an itch–scratch cycle. This repetitive mechanical stress can result in lichenification, worsening of epidermal barrier function, and enhanced cutaneous inflammation. Furthermore, a reduction of intraepidermal nerve fibers was previously described in lichenification. Aim: The aim of this study was to investigate the influence of chronic scratching on the epidermal neuroanatomy and on sensory changes, in particular the prevalence of hyperknesis and alloknesis in patients after mechanical, chemical, and electrical stimuli. Methods: Analyses were performed on pruritic lichenified (chronically scratched), pruritic non-lichenified (not chronically scratched), and non-pruritic non-lesional (unaected) skin areas of patients with inflammatory pruritus, i.e., atopic dermatitis (n = 35), and neuropathic pruritus, i.e., brachioradial pruritus (n = 34) vs. healthy matched controls (n = 64). Our fine-grained spatial skin characterization enabled specifically studying the dierential eects of chronic scratching in inflammatory and neuropathic itch. Results: Analysis of intraepidermal nerve fiber density showed rarefaction of fibers in all three skin areas of patients compared with healthy controls in both diagnoses. Even more, the two pruritic areas had significantly less nerve fibers than the unaected skin, whereas electrically induced itch was massively increased. Epidermal branching of the remaining nerve fibers in lichenified/chronically scratched skin was increased, particularly in patients with brachioradial pruritus, which may contribute to the pronounced local neuronal sensitivity. Hyperknesis and alloknesis were found to increase independently of lichenificat Conclusion: Our results indicate that chronic scratching may not aect intraepidermal nerve fiber density but leads to a stronger branching pattern of intraepidermal nerve fibers, which may contribute to local hypersensitivity. The increased sensitivity in the pruritic areas suggests mechanisms of peripheral sensitization, whereas the increased sensation of electrically and chemically induced itch in unaected skin indicates central sensitization for itch. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Non-Neuronal Kappa Opioid Pathway Profiling in the Skin of Different Chronic Pruritus–Associated Dermatoses
- Author
-
Wiegmann, Henning, Ständer, Sonja, Bobko, Svetlana, Renkhold, Lina, Lotts, Tobias, Zeidler, Claudia, Pereira, Manuel, and Agelopoulos, Konstantin
- Published
- 2023
- Full Text
- View/download PDF
16. Analysis of 325 Patients with Chronic Nodular Prurigo: Clinics, Burden of Disease and Course of Treatment
- Author
-
Gründel, Sonja Olivia, Pereira, Manuel P., Storck, Michael, Osada, Nani, Schneider, Gudrun, Ständer, Sonja, Zeidler, Claudia, and Universitäts- und Landesbibliothek Münster
- Subjects
Male ,chronic prurigo ,treatment ,610 Medicine and health ,antipruritic therapy ,pruritus ,prurigo nodularis ,Dermatology ,Cost of Illness ,RL1-803 ,Chronic Disease ,Medicine and health ,Quality of Life ,Humans ,Prurigo ,ddc:610 ,Neurodermatitis - Abstract
Chronic nodular prurigo presents with multiple pruriginous nodules and severe pruritus. This study aims to explore the treatment course and regimens in patients with chronic nodular prurigo and to analyse predictive factors contributing to therapeutic success. A total of 325 patients with chronic nodular prurigo (male 37.5%) were analysed concerning demographic data, pruritus intensity, medical history, psychological impairment, quality of life, treatment duration, regimens and outcome. These parameters were compared with 325 sex- and age-matched patients with chronic pruritus on non-lesional skin. Treatment success was dependent on duration and regime of treatment and independent of age, sex and initial itch intensity. Non-responders displayed a higher percentage of inflamed nodules, a higher portion of excoriated nodules and a higher impairment of quality of life and mood factors before initiation of treatment. Gabapentinoids and immunosuppressants proved to be the most successful therapeutic agents. Compared with patients with chronic pruritus, those with chronic nodular prurigo needed longer duration of therapy., Finanziert durch den Open-Access-Publikationsfonds der Westfälischen Wilhelms-Universität Münster (WWU Münster)
- Published
- 2022
17. Body dysmorphia in common skin diseases: Results of an observational, cross-sectional multi-centre study among dermatological out-patients in 17 European countries
- Author
-
Schut, Christina, Dalgard, Florence J., Bewley, Anthony, Evers, Andrea W.M., Gieler, Uwe, Lien, Lars, Sampogna, Francesca, Ständer, Sonja, Tomas-Aragones, Lucia, Vulink, Nienke, Finlay, Andrew Y., Legat, Franz J., Titeca, Geraldine, Jemec, Gregor B., Misery, Laurent, Szabó, Csanád, Grivcheva-Panovska, Vesna, Spillekom-van Koulil, Saskia, Balieva, Flora, Szepietowski, Jacek C., Reich, Adam, Roque Ferreira, Bárbara, Lvov, Andrey, Romanov, Dmitry, Marron, S.E., Gracia-Cazaña, Tamara, Svensson, Å., Altunay, Ilknur K., Thompson, Andrew, Zeidler, Claudia, Kupfer, Joerg, Heinemann, Tiziana, Sahin, Hüseyin, Kupsa, Romana, Narro-Bartenstein, Eva, Repelnig, Maria-Lisa, van Beugen, Sylvia, van Middendorp, Henriet, van Euler, Love, Bartczyszyn-Kmiecik, Aleksandra, Sawinska, Edyta, Adult Psychiatry, and ANS - Compulsivity, Impulsivity & Attention
- Subjects
Male ,ddc:610 ,Dermatology ,Body Dysmorphic Disorders ,Women's cancers Radboud Institute for Health Sciences [Radboudumc 17] ,Cross-Sectional Studies ,Medisinske Fag: 700 [VDP] ,Surveys and Questionnaires ,Acne Vulgaris ,Outpatients ,mental disorders ,Prevalence ,Humans ,Female ,03.02. Klinikai orvostan - Abstract
Background Body dysmorphic disorder (BDD) is a common psychiatric disorder associated with high costs for healthcare systems as patients may repeatedly ask for different, often not effective, interventions. BDD symptoms are more prevalent in patients with dermatological conditions than in the general population, but there are no large sample studies comparing the prevalence of BDD symptoms between patients with dermatological conditions and healthy skin controls. Objectives To compare the prevalence of BDD symptoms between patients with different dermatological conditions and healthy skin controls and to describe sociodemographic, physical and psychological factors associated with BDD symptoms to identify patients who may have a particularly high chance of having this condition. Methods This observational, cross-sectional, comparative multicentre study included 8295 participants: 5487 consecutive patients with different skin diseases (56% female) recruited among dermatological outpatients at 22 clinics in 17 European countries, and 2808 healthy skin controls (66% female). BDD symptoms were assessed by the Dysmorphic Concern Questionnaire. Sociodemographic data and information on psychological factors and physical conditions were collected. Each patient was given a dermatological diagnosis according to ICD-10 by a dermatologist. The study was registered with number DRKS00012745. Results The average participation rate of invited dermatological patients was 82.4% across all centres. BDD symptoms were five times more prevalent in patients with dermatological conditions than in healthy skin controls (10.5% vs. 2.1%). Patients with hyperhidrosis, alopecia and vitiligo had a more than 11-fold increased chance (adjusted Odds Ratio (OR) > 11) of having BDD symptoms compared with healthy skin controls, and patients with atopic dermatitis, psoriasis, acne, hidradenitis suppurativa, prurigo and bullous diseases had a more than sixfold increased chance (adjusted OR > 6) of having BDD symptoms. Using a logistic regression model, BDD symptoms were significantly related to lower age, female sex, higher psychological stress and feelings of stigmatization. Conclusions Clinical BDD symptoms are significantly associated with common dermatological diseases. As such symptoms are associated with higher levels of psychological distress and multiple unhelpful consultations, general practitioners and dermatologists should consider BDD and refer patients when identified to an appropriate service for BDD screening and management. What is already known about this topic? Body dysmorphic disorder (BDD) is a common psychiatric disorder with a prevalence of about 2% in the general population. Skin diseases pose a high psychological burden on patients. People with these problems often experience increased self-consciousness, skin-related shame and stigmatization. Single-centre studies including small samples of patients with skin conditions showed that these patients show symptoms of a similar nature to BDD more often than the general population. What does this study add? In this large multicentre study, BDD symptoms were fivefold more prevalent in dermatological patients than in healthy skin controls, and were related to young age, female sex, psychological stress and stigmatization experience. Certain patient groups (e.g. hyperhidrosis) had a greater than 11-fold increased chance of BDD symptoms compared with controls.Doctors should consider appearance-related concern and BDD more often and refer patients when needed to an appropriate service for assessment and treatment.
- Published
- 2022
18. Indikation zur Systemtherapie bei chronischer Prurigo: Kommentierte Checkliste für die Praxis.
- Author
-
Augustin, Matthias, Zeidler, Claudia, von Kiedrowski, Ralph, Metz, Martin, Darsow, Ulf, Raap, Ulrike, Legat, Franz Josef, Sebastian, Michael, Weisshaar, Elke, and Ständer, Sonja
- Published
- 2023
- Full Text
- View/download PDF
19. S2k Leitlinie: Diagnostik und Therapie des chronischen Pruritus.
- Author
-
Ständer, Sonja, Zeidler, Claudia, Augustin, Matthias, Darsow, Ulf, Kremer, Andreas E., Legat, Franz J., Koschmieder, Steffen, Kupfer, Jörg, Mettang, Thomas, Metz, Martin, Nast, Alexander, Raap, Ulrike, Schneider, Gudrun, Ständer, Hartmut, Streit, Markus, Schut, Christina, and Weisshaar, Elke
- Abstract
Copyright of Journal der Deutschen Dermatologischen Gesellschaft is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2022
- Full Text
- View/download PDF
20. S2k guideline: Diagnosis and treatment of chronic pruritus.
- Author
-
Ständer, Sonja, Zeidler, Claudia, Augustin, Matthias, Darsow, Ulf, Kremer, Andreas E., Legat, Franz J., Koschmieder, Steffen, Kupfer, Jörg, Mettang, Thomas, Metz, Martin, Nast, Alexander, Raap, Ulrike, Schneider, Gudrun, Ständer, Hartmut, Streit, Markus, Schut, Christina, and Weisshaar, Elke
- Abstract
Summary: Pruritus is a cross‐disciplinary leading symptom of numerous diseases and represents an interdisciplinary diagnostic and therapeutic challenge. In contrast to acute pruritus, chronic pruritus (CP) is a symptom of various diseases that is usually difficult to treat. Scratching and the development of scratch‐associated skin lesions can alter the original skin status. In the presence of an itch‐scratch‐cycle, even secondary diseases such as chronic prurigo can develop. Chronic pruritus leads to considerable subjective suffering of those affected, which can result in restrictions on the health‐related quality of life such as sleep disturbances, anxiety, depressiveness, experience of stigmatization and/or social withdrawal up to clinically relevant psychic comorbidities. Medical care of patients should therefore include (a) interdisciplinary diagnosis and therapy of the triggering underlying disease, (b) therapy of the secondary symptoms of pruritus (dermatological therapy, sleep promotion, in the case of an accompanying or underlying psychological or psychosomatic disease an appropriate psychological‐psychotherapeutic treatment) and (c) symptomatic antipruritic therapy. The aim of this interdisciplinary guideline is to define and standardize the therapeutic procedure as well as the interdisciplinary diagnosis of CP. This is the short version of the updated S2k‐guideline for chronic pruritus. The long version can be found at www.awmf.org. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
21. Clinical management of pruritus
- Author
-
Ständer, Sonja, Zeidler, Claudia, Magnolo, Nina, Raap, Ulrike, Mettang, Thomas, Kremer, Andreas E., Weisshaar, Elke, and Augustin, Matthias
- Published
- 2015
- Full Text
- View/download PDF
22. Klinisches Management bei Pruritus
- Author
-
Ständer, Sonja, Zeidler, Claudia, Magnolo, Nina, Raap, Ulrike, Mettang, Thomas, Kremer, Andreas E., Weisshaar, Elke, and Augustin, Matthias
- Published
- 2015
- Full Text
- View/download PDF
23. Healthcare Utilization and Treatment Patterns in Patients with Chronic Prurigo and Chronic Pruritus in Germany.
- Author
-
Ständer, Sonja, Garbe, Claudia, Hagenström, Kristina, Petersen, Jana, Zeidler, Claudia, and Augustin, Matthias
- Subjects
PRURIGO ,ITCHING ,DRUG prescribing ,MEDICAL care ,DRUGS ,DERMATOLOGISTS - Abstract
Background: To date, there have been no large studies describing real-world treatment of chronic prurigo (CPG) and pruritus (CPR) in Germany. Objective: To determine the healthcare utilization, treatment patterns, and costs associated with CPG and CPR in Germany. Methods: Retrospective analysis using anonymized claims data (German DAK-Gesundheit), based on a 40% sample of all insured adults of the DAK-Gesundheit on December 31, 2010 (N = 2,006,003). Results: Patients with CPR (prevalence 2.2%) most commonly visited general medicine/general practitioners (GPs, 80.1%), followed by gynecologists (66.1%) and dermatologists (51.1%). Patients with CPG (prevalence 0.2%) most commonly visited dermatologists (85.7%), GPs (78.1%), and ophthalmologists (47.2%). Of adult patients, 44% received at least one drug prescription. Two thirds of patients with a drug prescription received ≥1 topical drug (66.2%), and 54.3% ≥1 systemic drug (total costs of approximately EUR 550,000 and 2,500,000, respectively). Of patients with CPG, 33.8% received ≥1 systemic and 45.1% ≥1 topical drug prescription (costs of approximately EUR 360,000 vs. 105,000). Of patients with CPR, 23.5% received ≥1 systemic and 28.6% ≥1 topical drug prescription (costs of approximately EUR 2,000,000 vs. 500,000). Of patients with CPG, 5.8% received ≥1 phototherapy application vs. 1.2% of patients with CPR. Conclusions: These findings reflect the reality of care and can form a basis for the identification of overuse, underuse, and misuse in order to design CPG and CPR healthcare more effectively and efficiently. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
24. Pruritus in Autoimmune and Inflammatory Dermatoses
- Author
-
Zeidler, Claudia, Pereira, Manuel Pedro, Huet, Flavien, Misery, Laurent, Steinbrink, Kerstin, Ständer, Sonja, and Universitäts- und Landesbibliothek Münster
- Subjects
bullous pemphigoid ,atopic dermatitis ,integumentary system ,Mini Review ,substance P ,Pruritus ,Immunology ,Dermatitis ,psoriasis ,Skin Diseases ,Autoimmune Diseases ,body regions ,Medicine and health ,Humans ,itch ,ddc:610 ,skin and connective tissue diseases ,pruritus ,IL31 - Abstract
Pruritus in autoimmune and inflammatory dermatoses is a common symptom that can be severe and affect the quality of life of patients. In some diseases, pruritus is related to disorders activity and severity or may occur independent of the disease. Despite the high prevalence, the symptom is still underrated and there are only a few trials investigating the efficacy of drugs for disease-specific pruritus. In this review, the characteristics and possible pathomechanisms of pruritus in various dermatoses like autoimmune bullous diseases, connective tissue diseases as well as autoimmune-associated dermatoses (atopic dermatitis, psoriasis vulgaris) is illustrated. Additionally, studies analyzing the antipruritic treatment are discussed. Summarizing, the prevalence of pruritus in these diseases demonstrates the importance for symptom recognition and the need for an efficient antipruritic therapy.
- Published
- 2020
25. Brachioradial pruritus successfully treated with intravenous naloxone.
- Author
-
Zeidler, Claudia, Pereira, Manuel P., and Ständer, Sonja
- Subjects
- *
NALOXONE , *ITCHING , *TREATMENT effectiveness , *SPINAL stenosis , *SPINAL cord compression - Abstract
Dear Editor, Brachioradial pruritus (BRP) is typically located at the dorsolateral part of the forearms, mostly at the dermatomes C5/C6 but it may also involve other dermatomes at the arm and neck. Prior to treatment with naloxone, pruritus intensity was severe in all patients (worst pruritus intensity on the numerical rating scale [WI-NRS]: 8-10/10). [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
26. Introduction of a Specific Dermatological Rehabilitation Programme for Patients with Chronic Pruritus: A Pilot Study.
- Author
-
VON MARTIAL, Sophia, KOK, Lisa, GRÜNDEL, Sonja, AUGUSTIN, Matthias, BLOME, Christine, ZEIDLER, Claudia, STEINBRINK, Kerstin, STÄNDER, Sonja, and TSIANAKAS, Athanasios
- Subjects
TREATMENT programs ,MEDICAL care ,ITCHING ,MEDICAL rehabilitation ,PATIENT satisfaction ,PILOT projects ,NEUROPSYCHOLOGICAL rehabilitation - Abstract
Chronic pruritus is a common symptom, associated with several severe medical conditions, great psychological burden, and reduced quality of life. It also poses socio-economic challenges concerning patients' work loss and healthcare costs. In Germany, medical rehabilitation programmes represent an integral part of the medical care of patients with chronic inflammatory skin diseases. However, such programmes play only a rudimentary role in the treatment of other dermatological diseases, such as dermatological oncology, genetic skin diseases, and chronic pruritus. Therefore, a specific antipruritic dermatological rehabilitation programme was developed in cooperation between the Department of Dermatology of the Medical Rehabilitation Center Bad Bentheim and the Center for Chronic Pruritus of the University Hospital of Muenster, Germany. This prospective study compared short-term patient-reported outcomes (n = 121) at the beginning and end of the rehabilitation programme. The majority of subjects had chronic pruritus on primary diseased, inflamed skin. Significant improvements in pruritus intensity (p ≤ 0.001), quality of life (p ≤ 0.001), anxiety symptoms (p ≤ 0.001) and depression (p ≤ 0.001), as well as an overall patientrelevant benefit (Patient Benefit Index 2.6 ± 1.06) and treatment-related patients' satisfaction, were shown. This suggests that implementation of this standardized rehabilitation programme for treatment of patients with chronic pruritus was successful. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
27. Hand Pruritus: Clinical Profile, Functional Impairment and Diseaserelated Burden in a Prospective Cohort Study of 395 Patients.
- Author
-
NAU, Teresa Gabriele, RAU, Viola, ZEIDLER, Claudia, STÄNDER, Sonja, and PEREIRA, Manuel P.
- Subjects
QUALITY of life ,COHORT analysis ,LONGITUDINAL method ,ACTIVITIES of daily living ,SYMPTOMS ,ITCHING - Abstract
Human hands are complex structures essential for a variety of functions in everyday life. This study prospectively investigated the clinical features of hand pruritus and the resulting functional impairment and disease-related burden in 395 patients with chronic pruritus (210 females, median age 59 years). Moderate to very severe hand pruritus was reported by 91.2% of patients, while 79% perceived additional sensory symptoms, such as burning, pain or tingling. A long duration of pruritus occurred in most cases (> 6 months: 71.4%). A considerable proportion of patients showed moderate to severe impairment in the use of their hands (40.2%), performance of daily activities (65.0%) and quality of life (45.2%). Disease severity and burden is particularly high when both the palms and the backs of the hands are affected, and when pain is present simultaneously. Pruritus located on the hands is impairing and burdensome due to the functional relevance of the hands in everyday life. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
28. Chronic Pruritus of Unknown Origin: Clinical Profile and Disease-Related Burden.
- Author
-
PEREIRA, Manuel P., FARCAS, Alexandra, ZEIDLER, Claudia, and STÄNDER, Sonja
- Subjects
ITCHING ,QUALITY of life ,VISUAL analog scale - Abstract
Chronic pruritus of unknown origin is established when no underlying origin for pruritus can be determined. This retrospective cohort study aimed to determine the clinical profile and disease-related burden of chronic pruritus of unknown origin. A total of 263 patients (female/male: 154/109, median age 55 years) were included. Moderate to severe itch intensities were recorded (median average itch: 5.5/10, n = 200; median worst itch: 7.5/10, n = 199). In most cases pruritus lasted longer than 1 year (77.6%), occurred daily (68.2%), occurred in attacks (72.8%), and was often accompanied by dysaesthesias, such as burning, tingling and stinging. Quality of life was moderately impaired, while 22.2% and 12.4% of patients showed pathological anxiety and depression scores. Scratch lesions were associated with higher intensities of itch and greater impairment of quality of life, while women were more burdened by the disease than men. Chronic pruritus of unknown origin may occur at any age and the majority of patients endure severe itch with substantial disease-related burden. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
29. Validation of Psychometric Properties of the Itch Numeric Rating Scale for Pruritus Associated With Prurigo Nodularis: A Secondary Analysis of a Randomized Clinical Trial.
- Author
-
Kimel, Miriam, Zeidler, Claudia, Kwon, Paul, Revicki, Dennis, and Ständer, Sonja
- Published
- 2020
- Full Text
- View/download PDF
30. Comparison of itch characteristics and sleep in patients with brachioradial pruritus and notalgia paresthetica: A retrospective analysis from 2 itch centers
- Author
-
Lipman, Zoe M., Magnolo, Nina, Golpanian, Rachel S., Storck, Michael, Yosipovich, Gil, and Zeidler, Claudia
- Published
- 2021
- Full Text
- View/download PDF
31. Diagnostic and treatment algorithm for chronic nodular prurigo.
- Author
-
Ständer, Hartmut F., Elmariah, Sarina, Zeidler, Claudia, Spellman, Mary, and Ständer, Sonja
- Abstract
Chronic nodular prurigo (CNPG) is a subtype of chronic prurigo, also called prurigo nodularis, and a chronic skin condition characterized by intensely pruritic nodular lesions. Although the exact cause of CNPG is unknown, it appears to result from a repetitive itch-scratch cycle induced by neuronal sensitization to chronic pruritus. CNPG is associated with an underlying dermatologic condition in about half of patients, and it can also be attributed to systemic, neurologic, psychogenic, or unknown causes. For most patients, multiple underlying causes are identified. Patients with CNPG often experience impaired quality of life, sleep disturbance, anxiety, and depression. To encourage consistent and accurate diagnosis and treatment of CNPG across regions, we are proposing a diagnostic and treatment algorithm that includes initial assessment of core symptoms, detailed dermatologic history and clinical examination, patient-reported outcomes, diagnostic workup, and recommended therapies. This information is supplemented with photographs to illustrate clinical appearance and disease severity. Because CNPG is often multifactorial and it can take months to years for lesions to heal, interdisciplinary cooperation and long-term management are important. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
32. Challenges in Clinical Research and Care in Pruritus.
- Author
-
PEREIRA, Manuel P., ZEIDLER, Claudia, STORCK, Michael, AGELOPOULOS, Konstantin, PHILIPP-DORMSTON, Wolfgang G., ZINK, Alexander, and STÄNDER, Sonja
- Subjects
- *
ITCHING , *TRANSLATIONAL research , *PATHOLOGICAL physiology - Abstract
Chronic pruritus is a frequent global condition. The pathophysiology, underlying aetiology, clinical manifestation, associated burden and response to therapy of chronic pruritus varies from patient to patient, making clinical research and management of this condition challenging. There are still several unmet needs, such as the need to standardize translational research protocols, diagnostic and therapeutic procedures and to enhance the knowledge of the humanistic and economic burden associated with chronic pruritus. Basic and clinical research is of the utmost importance to target these matters. Clinical research has the potential to identify new relevant mechanisms in affected patients, which may lead to identification of novel therapy targets. This article discusses in depth current shortcomings in the daily care of patients with chronic pruritus and the challenges clinical researchers and physicians treating chronic pruritus face in addressing these matters. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
33. Generalisierter chronischer Pruritus bei Fibromyalgie.
- Author
-
Görg, Max, Zeidler, Claudia, Pereira, Manuel P., and Ständer, Sonja
- Published
- 2021
- Full Text
- View/download PDF
34. Generalized chronic pruritus with fibromyalgia.
- Author
-
Görg, Max, Zeidler, Claudia, Pereira, Manuel P., and Ständer, Sonja
- Published
- 2021
- Full Text
- View/download PDF
35. BAG3 and SYNPO (synaptopodin) facilitate phospho-MAPT/Tau degradation via autophagy in neuronal processes.
- Author
-
Ji, Changyi, Tang, Maoping, Zeidler, Claudia, Höhfeld, Jörg, and Johnson, Gail VW
- Abstract
A major cellular catabolic pathway in neurons is macroautophagy/autophagy, through which misfolded or aggregation-prone proteins are sequestered into autophagosomes that fuse with lysosomes, and are degraded. MAPT (microtubule-associated protein tau) is one of the protein clients of autophagy. Given that accumulation of hyperphosphorylated MAPT contributes to the pathogenesis of Alzheimer disease and other tauopathies, decreasing endogenous MAPT levels has been shown to be beneficial to neuronal health in models of these diseases. A previous study demonstrated that the HSPA/HSP70 co-chaperone BAG3 (BCL2-associated athanogene 3) facilitates endogenous MAPT clearance through autophagy. These findings prompted us to further investigate the mechanisms underlying BAG3-mediated autophagy in the degradation of endogenous MAPT. Here we demonstrate for the first time that BAG3 plays an important role in autophagic flux in the neurites of mature neurons (20–24 days in vitro [DIV]) through interaction with the post-synaptic cytoskeleton protein SYNPO (synaptopodin). Loss of either BAG3 or SYNPO impeded the fusion of autophagosomes and lysosomes predominantly in the post-synaptic compartment. A block of autophagy leads to accumulation of the autophagic receptor protein SQSTM1/p62 (sequestosome 1) as well as MAPT phosphorylated at Ser262 (p-Ser262). Furthermore, p-Ser262 appears to accumulate in autophagosomes at post-synaptic densities. Overall these data provide evidence of a novel role for the co-chaperone BAG3 in synapses. In cooperation with SYNPO, it functions as part of a surveillance complex that facilitates the autophagic clearance of MAPT p-Ser262, and possibly other MAPT species at the post-synapse. This appears to be crucial for the maintenance of a healthy, functional synapse.Abbreviations: aa: amino acids; ACTB: actin beta; BafA1: bafilomycin A
1; BAG3: BCL2 associated athanogene 3; CQ chloroquine; CTSL: cathepsin L; DIV: days in vitro; DLG4/PSD95: discs large MAGUK scaffold protein 4; HSPA/HSP70: heat shock protein family A (Hsp70); MAP1LC3B/LC3B: microtubule associated protein 1 light chain 3 beta; MAP2: microtubule associated protein 2; MAPT: microtubule associated protein tau; p-Ser262: MAPT phosphorylated at serine 262; p-Ser396/404: MAPT phosphorylated at serines 396 and 404; p-Thr231: MAPT phosphorylated at threonine 231; PBS: phosphate buffered saline; PK: proteinase K; scr: scrambled; shRNA: short hairpin RNA; SQSTM1/p62 sequestosome 1; SYN1: synapsin I; SYNPO synaptopodin; SYNPO2/myopodin: synaptopodin 2; VPS: vacuolar protein sorting [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
36. Pruritus in Autoimmune and Inflammatory Dermatoses.
- Author
-
Zeidler, Claudia, Pereira, Manuel Pedro, Huet, Flavien, Misery, Laurent, Steinbrink, Kerstin, and Ständer, Sonja
- Subjects
ITCHING ,SKIN diseases ,CONNECTIVE tissue diseases ,ATOPIC dermatitis ,DRUG efficacy ,BULLOUS pemphigoid - Abstract
Pruritus in autoimmune and inflammatory dermatoses is a common symptom that can be severe and affect the quality of life of patients. In some diseases, pruritus is related to disorders activity and severity or may occur independent of the disease. Despite the high prevalence, the symptom is still underrated and there are only a few trials investigating the efficacy of drugs for disease-specific pruritus. In this review, the characteristics and possible pathomechanisms of pruritus in various dermatoses like autoimmune bullous diseases, connective tissue diseases as well as autoimmune-associated dermatoses (atopic dermatitis, psoriasis vulgaris) is illustrated. Additionally, studies analyzing the antipruritic treatment are discussed. Summarizing, the prevalence of pruritus in these diseases demonstrates the importance for symptom recognition and the need for an efficient antipruritic therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
37. Validation of a Comprehensive Set of Pruritus Assessment Instruments: The Chronic Pruritus Tools Questionnaire PRURITOOLS.
- Author
-
VERWEYEN, Emely, STÄNDER, Sonja, KREITZ, Kiana, HÖBEN, Inga, OSADA, Nani, GERNART, Marvin, RIEPE, Claudia, PEREIRA, Manuel, BLOME, Christine, AUGUSTIN, Matthias, and ZEIDLER, Claudia
- Subjects
ITCHING ,INTRACLASS correlation ,RAPID tooling ,STATISTICAL reliability ,TEST validity - Abstract
Few studies have validated standard measurement instruments for evaluation of chronic pruritus. The Chronic Pruritus Tools Questionnaire PRURITOOLS assembles a set of instruments for the assessment of pruritus, such as the visual analogue scale (horizontal 100-mm line), numerical rating scale (0-10), verbal rating scale, and information on pruritus quality and improvement during therapy. This study, with 40 subjects, analysed PRURITOOLS regarding convergent validity and test-retest reliability (60 min), followed by a feasibility questionnaire. Test-retest reliability for PRURITOOLS items was excellent (intraclass correlation coefficient 0.84-1). Strong to very strong correlations between the pruritus intensity scales indicated convergent validity. The feasibility questionnaire showed an overall acceptance of PRURITOOLS, and the majority of subjects (82.5%) considered it an appropriate questionnaire to measure pruritus. In conclusion, PRURITOOLS offers validated tools for rapid pruritus assessment in routine care or endpoints of clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
38. Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU).
- Author
-
TSIANAKAS, Athanasios, ZEIDLER, Claudia, RIEPE, Claudia, BOROWSKI, Matthias, FORNER, Caroline, GERSS, Joachim, METZ, Martin, STAUBACH, Petra, RAAP, Ulrike, KAATZ, Martin, URBAN, Marc, LUGER, Thomas A., and STÄNDER, Sonja
- Subjects
- *
SUBSTANCE P receptors , *ITCHING , *SUBSTANCE P - Abstract
The aim of this multicentre, randomized, double-blind, placebo-controlled, cross-over, phase-II study was to determine the antipruritic effect of aprepitant vs. placebo in 58 patients with anti-histamine-refractory chronic pruritus in chronic nodular prurigo. Patients were randomized to receive either first oral aprepitant 80 mg/day or placebo for 4 weeks. Following a 2-week wash-out phase, the patients were crossedover to receive the other treatment for 4 weeks. Primary efficacy criterion was the intra-individual difference between mean itch intensity (visual analogue scale) at baseline compared with the end of treatment period. Prurigo lesions, pruritus course, quality of life, patient benefits, and safety were secondary parameters. No significant differences were found between aprepitant treatment and placebo for any of the parameters investigated. Under the experimental conditions of the study, aprepitant, 80 mg daily for 4 weeks, did not have an antipruritic effect in patients with chronic prurigo. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
39. Exploratory Study of Intracutaneous Histamine Stimulation in Patient Populations with Chronic Pruritus.
- Author
-
TSIANAKAS, Athanasios, NIPPE, Nadine, HAMPER, Christina Maria, CORDES, Anna Friederike, ZEIDLER, Claudia, SCHMELZ, Martin, and STÄNDER, Sonja
- Subjects
ITCHING ,HISTAMINE - Abstract
Chronic pruritus can be a diagnostic sign of an underlying disease. In the intracutaneous histamine test, histamine (one of the best-known inducers of pruritus) may cause different reaction patterns depending on the underlying disease. The aim of this study was to determine if an intracutaneous injection of histamine can differentiate between the causes of chronic pruritus and thus be used as a diagnostic test in chronic pruritus of unknown aetiology. A total of 140 subjects with chronic pruritus with various dermatological, systemic or neurological diseases were included. The intracutaneous histamine test was performed once on each subject. Erythema, wheal and pruritus intensity were measured and analysed. Significantly greater wheal size was observed in patients with systemic or multifactorial causes. In general, there was a significant correlation between age and wheal size. Also, noticeable differences were found between males and females regarding pruritus and wheal size. In summary, the exact type of chronic pruritus could not be clearly determined based on the results of the intracutaneous histamine test. However, the results provide valuable insights into specific reaction patterns to experimental histamine-induced itch, e.g. sex-specific differences in the neurophysiology of pruritus, which should be considered in future studies. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
40. Usability of Validated Sleep-assessment Questionnaires in Patients with Chronic Pruritus: An Interview-based Study.
- Author
-
Suilmann, Theresa, Zeidler, Claudia, Osada, Nani, Riepe, Claudia, and Ständer, Sonja
- Subjects
- *
ITCHING , *CLINICAL trials , *PRURIGO , *QUESTIONNAIRES , *INSOMNIA , *DIAGNOSIS - Abstract
Impaired sleep due to nocturnal pruritus is a common symptom in patients with chronic pruritus. How ever, there is no standardized, simplified instrument for assessing sleep-related problems in patients with chronic pruritus. After a literature search, we conducted 50 interviews with patients with chronic pruritus and tested 12 items most frequently used in routine sleep questionnaires. Afterwards, 2 sleep assessment questionnaires (Pittsburgh Sleep Quality Index; Regensburg Insomnia Scale) were selected for use in 88 patients with chronic pruritus with sleep impairment due to pruritus. They were completed twice; once before optimizing their individual pruritus therapy and once again after 4 weeks. During the latter survey, 21 patients reported that pruritus no longer negatively affected their sleep. These patients also achieved a significant improvement in their sleeping behaviour in the Regensburg Insomnia Scale. Therefore, the Regensburg Insomnia Scale appears to be well-suited to assessing sleep impairment in patients with chronic pruritus. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
41. Minimal Clinically Important Difference in Chronic Pruritus Appears to be Dependent on Baseline Itch Severity.
- Author
-
RIEPE, Claudia, OSADA, Nani, REICH, Adam, AUGUSTIN, Matthias, ZEIDLER, Claudia, and STÄNDER, Sonja
- Subjects
ITCHING ,CHRONIC diseases ,SEVERITY of illness index - Abstract
The article reports the minimal clinically important difference (MCID) difference in chronic pruritus appearing to be dependent on baseline itch severity. Topics include how MCID depends on the method of calculation, response to an instrument and anchor measure reliability; and investigating the overall MCID in chronic pruritus using a visual analogue scale (VAS) and numeric rating scale (NRS).
- Published
- 2019
- Full Text
- View/download PDF
42. Chronic Prurigo of Nodular Type: A Review.
- Author
-
ZEIDLER, Claudia, TSIANAKAS, Athanasios, PEREIRA, Manuel, STÄNDER, Hartmut, YOSIPOVITCH, Gil, and STÄNDER, Sonja
- Subjects
- *
PRURIGO , *ITCHING , *NODULAR disease , *STEROIDS , *CAPSAICIN , *THERAPEUTICS - Abstract
Prurigo nodularis (PN) is a subtype of chronic prurigo presenting single to multiple symmetrically distributed, hyperkeratotic and intensively itching papules and nodules. PN evolves along with chronic pruritus in the context of diverse dermatological, systemic, neurological or psychiatric conditions. Permanent scratching is possibly a major trigger of PN, although its exact pathophysiology remains unclear. Current state-of-the-art therapy for PN consists of topical steroids, capsaicin, calcineurin inhibitors, ultraviolet (UV) therapy, systemic administration of gabapentinoids, µ-opioid receptor antagonists, antidepressants or immunosuppressants. Novel treatment concepts, such as inhibitors of neurokinin-1, opioid and interleukin-31 receptors, have been developed and are currently being clinically tested. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
43. Validation of Pruritus Measures Gathered with the Electronic Patient-reported Outcome System MoPat.
- Author
-
STORCK, Michael, ZEIDLER, Claudia, REHR, Mirjam, RIEPE, Claudia, DUGAS, Martin, STÄNDER, Sonja, and SOTO-REY, Iñaki
- Subjects
- *
ITCHING , *PATIENT surveys , *PATIENT monitoring , *HEALTH outcome assessment , *QUALITY of life measurement - Abstract
In order to improve diagnosis and treatment, physicians require information about the social context and quality of life of their patients. The Center for Chronic Pruritus at the University Hospital Münster achieves this goal using the electronic patient-reported outcome system "Mobile Patient Survey", which assesses pruritus and quality of life measures. The aim of this study is to evaluate the consistency and reliability of such measures. A total of 42 patients, age range 19-82 years, participated in the study and were asked to assess the measures at baseline via a paper questionnaire, and to use the "Mobile Patient Survey" at baseline and after 1 h in order to test reliability. Statistical analysis was performed using coefficient rc for metric variables and weighted kappa κw for categorical vari- ables. The internal consistency of all measures was unaffected. It was shown that 6 out of 7 measures can be assessed without loss of reliability. It is recommended that questionnaires for electronic usage are assessed for validity and reliability. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
44. Brachioradial Pruritus and Notalgia Paraesthetica: A Comparative Observational Study of Clinical Presentation and Morphological Pathologies.
- Author
-
PEREIRA, Manuel P., LÜLING, Hannah, DIECKHÖFER, Annette, STEINKE, Sabine, ZEIDLER, Claudia, and STÄNDER, Sonja
- Subjects
ITCHING ,BACK diseases ,ARM diseases ,SKIN diseases ,QUALITY of life ,CAPSAICIN ,NEUROPATHY ,PAIN management - Abstract
Brachioradial pruritus (BRP) and notalgia paraesthetica (NP) represent 2 of the most common neuropathic itch syndromes. A total of 58 consecutive patients presenting at the Center for Chronic Pruritus, University Hospital Münster, were analysed with regard to clinical presentation, anatomical and morphological pathologies, impairment in quality of life, and response to treatment with topical capsaicin. Patients with BRP reported stinging and burning more often than those with NP. In the BRP group structural magnetic resonance imaging abnormalities more frequently correlated with localization of the symptoms compared with in patients with NP. In addition, intraepidermal nerve fibre density was decreased in lesional skin in patients with BRP, but not in those with NP, confirming the neuropathic origin in BRP. Topical capsaicin resulted in a significantly higher alleviation of itch and pain intensity and improvement in quality of life in patients with BRP compared with those with NP, which may reflect clinical and aetiological differences between the conditions. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
45. Other Forms of Neuropathic Pruritus.
- Author
-
Stumpf, Astrid, Zeidler, Claudia, and Ständer, Sonja
- Published
- 2016
- Full Text
- View/download PDF
46. Brachioradial Pruritus.
- Author
-
Stumpf, Astrid, Zeidler, Claudia, and Ständer, Sonja
- Published
- 2016
- Full Text
- View/download PDF
47. S2k-Leitlinie zur Diagnostik und Therapie des chronischen Pruritus - Update - Kurzversion.
- Author
-
Ständer, Sonja, Zeidler, Claudia, Augustin, Matthias, Bayer, Gudrun, Kremer, Andreas E., Legat, Franz J., Maisel, Peter, Mettang, Thomas, Metz, Martin, Nast, Alexander, Niemeier, Volker, Raap, Ulrike, Schneider, Gudrun, Ständer, Hartmut F., Staubach, Petra, Streit, Markus, and Weisshaar, Elke
- Abstract
Copyright of Journal der Deutschen Dermatologischen Gesellschaft is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2017
- Full Text
- View/download PDF
48. S2k Guidelines for the diagnosis and treatment of chronic pruritus - update - short version.
- Author
-
Ständer, Sonja, Zeidler, Claudia, Augustin, Matthias, Bayer, Gudrun, Kremer, Andreas E., Legat, Franz J., Maisel, Peter, Mettang, Thomas, Metz, Martin, Nast, Alexander, Niemeier, Volker, Raap, Ulrike, Schneider, Gudrun, Ständer, Hartmut F., Staubach, Petra, Streit, Markus, and Weisshaar, Elke
- Abstract
Associated with a host of different diseases, pruritus is a cardinal symptom that poses an interdisciplinary diagnostic and therapeutic challenge. Over time, that symptom may progress independently of the initial cause, thus losing its function as a warning sign and turning into a clinically relevant disease of its own. In Germany, approximately 13.5 % of the general population are affected by chronic pruritus, with an incidence of 7 %. All forms of chronic pruritus require targeted treatment consisting of (a) diagnosis and management of the underlying disease, (b) dermatological treatment of primary or secondary (for example, dry skin, scratch lesions) symptoms, (c) symptomatic antipruritic treatment, and (d) psychological/psychotherapeutic treatment in case of an underlying or associated psychological or psychosomatic condition. Medical care of patients with chronic pruritus should therefore include an interdisciplinary approach, in particular with respect to diagnosis and therapy of the underlying disease as well as in terms of the management of treatment and adverse events. The objective of the present interdisciplinary guidelines is to define and standardize diagnostic and therapeutic procedures in patients with chronic pruritus. This is a short version of the current S2 guidelines on chronic pruritus. The long version may be found at . [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
49. ItchApp©: An App-based eDiary for Assessment of Chronic Pruritus in Clinical Trials.
- Author
-
GERNART, Marvin, TSIANAKAS, Athanasios, ZEIDLER, Claudia, RIEPE, Claudia, OSADA, Nani, PIHAN, David, and STÄNDER, Sonja
- Subjects
ITCHING ,CLINICAL trials ,ELECTRONIC health records ,RANDOMIZED controlled trials ,DIAGNOSIS - Abstract
Performing a reliable assessment of chronic pruritus remains a challenge. Electronic diaries are often used, but many of the scales have not been validated. ItchApp
© was developed for Android smartphones in order to address this lack. A total of 40 subjects with chronic pruritus completed questionnaires both on paper and with ItchApp© (verbal rating scale, numerical rating scale, dynamic pruritus score) in order to validate the software application. Strong correlations were found for test–retest reliability (intraclass correlation coefficient: 0.865-0.977) and convergent validity (Spearman's r: 0.442-0.924). A feasibility questionnaire for ItchApp© revealed a high level of user friendliness and compliance. This was confirmed in a randomized controlled trial with 68 subjects, for which the clinically important difference in the numerical rating scale values for ItchApp© was calculated (2.61 points). In summary, ItchApp© is a recently developed eDiary that can provide experts with a reliable evaluation of patients with chronic pruritus. It will be made available for future clinical trials. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
50. Dynamic Pruritus Score: Evaluation of the Validity and Reliability of a New Instrument to Assess the Course of Pruritus.
- Author
-
STÄNDER, Sonja, BLOME, Christine, ANASTASIADOU, Zografia, ZEIDLER, Claudia, JUNG, Katharina Anna, TSIANAKAS, Athanasios, Gitta NEUFANG, Gitta, and AUGUSTIN, Matthias
- Subjects
TEST validity ,TEST reliability ,ITCHING ,VISUAL analog scale ,QUALITY of life - Abstract
Currently valid itch intensity scales, such as the visual analogue scale (VAS), are indispensable, but they can be influenced by the patient's overall health status. The aim of this study was to evaluate the reliability and validity of the Dynamic Pruritus Score (DPS), a new instrument comparing reduction in current pruritus with a defined earlier time-point. Eighty-one randomly selected adults (50 females, mean age 53.9 years) recorded their pruritus at visit 1 and repeatedly at visit 2 on the DPS, VAS, numerical rating scale, and on health status questionnaires (EuroQol; EQ-5D), skin-related quality of life (Dermatology Life Quality Index; DLQI), anxiety and depression (Hospital Anxiety and Depression Scale; HADS) and patient benefit (Patient Benefit Index; PBI). Intraclass correlation showed high reliability for both DPS and VAS (r > 0.9, p < 0.001), while the DPS has shown higher concurrent validity (r
DPS to PBI = 0.570; p < 0.001). The DPS can then be considered an alternative instrument to the VAS for assessment of pruritus in adults. Further research is needed to confirm these results with a more representative sample size. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.